Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Trabectedin and its potential in the treatment of soft tissue sarcoma

Authors Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Published 8 February 2008 Volume 2008:4(1) Pages 109—116

DOI https://doi.org/10.2147/TCRM.S1174

Philippe A Cassier1, Armelle Dufresne1, Jean-Yves Blay1,2,3, Jérôme Fayette2,3

1Unité de Jour d’Oncologie Médicale Multidisciplinaire, Hôpital Edouard Herriot, Lyon, France; 2Département d’Oncologie Médicale, Centre Léon Bérard, Lyon, France; 3Unité INSERM 590, Equipe Cytokine et Cancer, Centre Léon Bérard, Lyon, France

Abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Phase I trials have established the standard regimen as 1500 µg/m² 24-hour continuous infusion repeated every 3 weeks. Several phase II trials have shown response in 5%–10% of unselected patients with soft tissue sarcoma failing prior chemotherapy and disease stabilisation in 30%–40%. Furthermore, prolonged disease control has been described in 15%–20% of patients. Toxicities are mainly haematological and hepatic with grade 3–4 neutropenia and thrombocytopenia observed in approximately 50% and 20% of patients respectively, and grade 3–4 elevation of liver enzymes observed in 35%–50% of patients treated with trabectedin. Current research focuses on the identification of predictive factors for patients with soft tissue sarcoma treated with trabectedin.

Keywords: chemotherapy, sarcoma, drug development, DNA repair

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

Advances in the use of topical imiquimod to treat dermatologic disorders

Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali

Therapeutics and Clinical Risk Management 2008, 4:87-97

Published Date: 8 February 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008

Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial

Hong-nü Chu, Mei-juan Shen

Therapeutics and Clinical Risk Management 2008, 4:287-290

Published Date: 8 February 2008